Calliditas Therapeutics
Richard Philipson has extensive work experience in the pharmaceutical industry. Richard currently serves as the Chief Medical Officer at Calliditas Therapeutics AB since 2020. Prior to this, they held the same position at Trizell Ltd from 2016 to 2020, where they oversaw clinical and medical governance for gene therapy programs and clinical studies in oncology indications. At Takeda, they served as the Executive Medical Director from 2014 to 2016, responsible for early clinical portfolio development and serving as the Responsible Officer. Before Takeda, they worked at GlaxoSmithKline from 1998 to 2014, where they held various roles including Disease Area Head and Acting Chief Medical Officer, Director of Discovery Medicine, and Director of Clinical Development. Richard also worked as a Research Physician at Hoechst Marion Roussel from 1996 to 1998.
Richard Philipson attended the University of London from 1982 to 1988. The degree name and field of study during this period are unknown.
This person is not in any offices
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.